News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,758 Results
Type
Article (40005)
Company Profile (250)
Press Release (664502)
Multimedia
Podcasts (58)
Webinars (14)
Section
Business (204273)
Career Advice (2011)
Deals (35453)
Drug Delivery (95)
Drug Development (81137)
Employer Resources (172)
FDA (16249)
Job Trends (14886)
News (345494)
Policy (32605)
Tag
Academia (2556)
Accelerated approval (9)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (108)
Alzheimer's disease (1438)
Antibody-drug conjugate (ADC) (151)
Approvals (16244)
Artificial intelligence (307)
Autoimmune disease (28)
Automation (18)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (121)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (33)
Breast cancer (364)
Cancer (2852)
Cardiovascular disease (211)
Career advice (1681)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (496)
Cervical cancer (22)
Clinical research (66832)
Collaboration (1011)
Company closure (3)
Compensation (686)
Complete response letters (22)
COVID-19 (2624)
CRISPR (56)
C-suite (321)
Cystic fibrosis (111)
Data (2982)
Decentralized trials (2)
Denatured (20)
Depression (60)
Diabetes (346)
Diagnostics (6423)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (135)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (124)
Earnings (87437)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113724)
Executive appointments (845)
FDA (17888)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (928)
Gene editing (129)
Generative AI (22)
Gene therapy (372)
GLP-1 (780)
Government (4499)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (146)
Immuno-oncology (8)
Indications (39)
Infectious disease (2795)
Inflammatory bowel disease (147)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (119)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3636)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (491)
Leadership (18)
Legal (7929)
Liver cancer (79)
Lung cancer (399)
Lymphoma (208)
Machine learning (11)
Management (58)
Manufacturing (381)
MASH (90)
Medical device (13456)
Medtech (13461)
Mergers & acquisitions (19575)
Metabolic disorders (845)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (31)
Neuroscience (2111)
NextGen: Class of 2025 (6517)
Non-profit (4488)
Now hiring (47)
Obesity (425)
Opinion (217)
Ovarian cancer (100)
Pain (104)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (295)
Patient recruitment (160)
Peanut (50)
People (57675)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20827)
Phase II (29439)
Phase III (21907)
Pipeline (1620)
Policy (198)
Postmarket research (2563)
Preclinical (8866)
Press Release (64)
Prostate cancer (139)
Psychedelics (36)
Radiopharmaceuticals (253)
Rare diseases (455)
Real estate (5917)
Recruiting (66)
Regulatory (22621)
Reports (50)
Research institute (2325)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (156)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3587)
State (2)
Stomach cancer (14)
Supply chain (75)
Tariffs (57)
The Weekly (36)
Vaccines (778)
Venture capital (53)
Weight loss (255)
Women's health (46)
Worklife (16)
Date
Today (43)
Last 7 days (386)
Last 30 days (1806)
Last 365 days (31215)
2025 (16654)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29264)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38202)
Australia (6233)
California (7409)
Canada (2351)
China (669)
Colorado (320)
Connecticut (316)
Delaware (192)
Europe (82089)
Florida (1115)
Georgia (247)
Hawaii (1)
Idaho (59)
Illinois (636)
India (26)
Indiana (360)
Iowa (16)
Japan (227)
Kansas (108)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1019)
Massachusetts (5510)
Michigan (245)
Minnesota (448)
Mississippi (3)
Missouri (89)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2068)
New Mexico (28)
New York (2082)
North Carolina (1077)
North Dakota (8)
Northern California (3261)
Ohio (235)
Oklahoma (16)
Oregon (34)
Pennsylvania (1609)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2768)
Tennessee (125)
Texas (1114)
United States (27470)
Utah (219)
Virginia (183)
Washington D.C. (72)
Washington State (629)
West Virginia (4)
Wisconsin (65)
704,758 Results for "vaxxas inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vaxxas Secures New U.S. Patent For its Needle-Free Vaccination Manufacturing Technology
March 19, 2025
·
5 min read
Press Releases
Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery
February 18, 2025
·
6 min read
Press Releases
Vaxxas Appoints Leading Global Vaccine Experts as the Company Advances its Needle-Free Vaccination Technology Towards Late-Stage Clinical Trials
February 6, 2025
·
6 min read
Press Releases
Newly Published Data Supports Effective Delivery of DNA-Based Vaccines Using Vaxxas’ High-Density Microarray Patch (HD-MAP) Delivery Technology
March 5, 2025
·
8 min read
Press Releases
Vaxxas and CEPI Advance US$4.8 million (AU$7.2 million) Program for Needle-Free Thermostable mRNA Vaccines
January 23, 2025
·
8 min read
Press Releases
Vaxxas Expands Global Intellectual Property Portfolio for Exclusive Manufacture and Sale of Needle-Free Vaccination Technology
November 25, 2024
·
5 min read
Press Releases
Vaxxas Initiates Phase I Clinical Trial of Pre-Pandemic Avian Influenza A Virus (H7N9) Vaccine Delivered Using Vaxxas’ Novel High-Density Microarray Patch (HD-MAP)
September 11, 2024
·
6 min read
Press Releases
Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)
October 28, 2024
·
6 min read
Business
Vaxxas Appoints Rochelle Chaiken, M.D., as Chief Medical Officer
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, announced the appointment of Rochelle Chaiken, M.D., as Chief Medical Officer.
June 5, 2023
·
4 min read
Genetown
Vaccine Journal Highlights the Potential for Self-Administration of Vaccines Using Vaxxas High-Density Microarray Patch (HD-MAP)
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced a publication in the journal Vaccine entitled “Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.”
October 18, 2023
·
6 min read
1 of 70,476
Next
